NCT00851500

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of K-604 for the treatment of atherosclerosis.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
210

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Feb 2009

Geographic Reach
1 country

19 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2009

Completed
23 days until next milestone

First Submitted

Initial submission to the registry

February 24, 2009

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 26, 2009

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2011

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2011

Completed
Last Updated

August 17, 2011

Status Verified

August 1, 2011

Enrollment Period

2.3 years

First QC Date

February 24, 2009

Last Update Submit

August 15, 2011

Conditions

Keywords

atherosclerosiscarotid artery disease

Outcome Measures

Primary Outcomes (1)

  • Change from baseline in plaque composition over 6 months

    6 months

Secondary Outcomes (1)

  • Change from baseline in plaque size over 6 months.

    6 months

Study Arms (3)

low dose K-604

EXPERIMENTAL
Drug: K-604

high dose K-604

EXPERIMENTAL
Drug: K-604

placebo

PLACEBO COMPARATOR
Other: Placebo

Interventions

K-604DRUG

K-604 is given for 26 weeks

high dose K-604low dose K-604
PlaceboOTHER

placebo tablets are given for 26 weeks

placebo

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • moderate carotid artery stenosis

You may not qualify if:

  • history of arteritis
  • heavily calcified plaque
  • uncontrolled hypertension
  • poorly controlled diabetes
  • hypercholesterolemia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (19)

Unknown Facility

Chandler, Arizona, United States

Location

Unknown Facility

Litchfield Park, Arizona, United States

Location

Unknown Facility

Phoenix, Arizona, United States

Location

Unknown Facility

Los Angeles, California, United States

Location

Unknown Facility

San Diego, California, United States

Location

Unknown Facility

Clearwater, Florida, United States

Location

Unknown Facility

Jacksonville, Florida, United States

Location

Unknown Facility

St Louis, Missouri, United States

Location

Unknown Facility

Buffalo, New York, United States

Location

Unknown Facility

Oklahoma City, Oklahoma, United States

Location

Unknown Facility

Carrollton, Texas, United States

Location

Unknown Facility

Dallas, Texas, United States

Location

Unknown Facility

Houston, Texas, United States

Location

Unknown Facility

Plano, Texas, United States

Location

Unknown Facility

Norfolk, Virginia, United States

Location

Unknown Facility

Virginia Beach, Virginia, United States

Location

Unknown Facility

Olympia, Washington, United States

Location

Unknown Facility

Renton, Washington, United States

Location

Unknown Facility

Seattle, Washington, United States

Location

MeSH Terms

Conditions

AtherosclerosisCarotid Artery Diseases

Interventions

(2-(4-(2-benzimidazol-2ylthio)ethyl)piperazin-1yl)-N-(2,4-bis(methylthio)-6-methyl-3-pyridyl)acetamide

Condition Hierarchy (Ancestors)

ArteriosclerosisArterial Occlusive DiseasesVascular DiseasesCardiovascular DiseasesCerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

February 24, 2009

First Posted

February 26, 2009

Study Start

February 1, 2009

Primary Completion

June 1, 2011

Study Completion

August 1, 2011

Last Updated

August 17, 2011

Record last verified: 2011-08

Locations